CN110279738A - A kind of extracting method of antidepressant spermidine active component and the purposes of spermidine effective part extract - Google Patents
A kind of extracting method of antidepressant spermidine active component and the purposes of spermidine effective part extract Download PDFInfo
- Publication number
- CN110279738A CN110279738A CN201910596030.6A CN201910596030A CN110279738A CN 110279738 A CN110279738 A CN 110279738A CN 201910596030 A CN201910596030 A CN 201910596030A CN 110279738 A CN110279738 A CN 110279738A
- Authority
- CN
- China
- Prior art keywords
- spermidine
- antidepressant
- effective part
- effective
- extract
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- ATHGHQPFGPMSJY-UHFFFAOYSA-N spermidine Chemical compound NCCCCNCCCN ATHGHQPFGPMSJY-UHFFFAOYSA-N 0.000 title claims abstract description 150
- 229940063673 spermidine Drugs 0.000 title claims abstract description 74
- 230000001430 anti-depressive effect Effects 0.000 title claims abstract description 30
- 239000000284 extract Substances 0.000 title claims abstract description 27
- 239000000935 antidepressant agent Substances 0.000 title claims abstract description 19
- 238000000034 method Methods 0.000 title claims abstract description 17
- 229940005513 antidepressants Drugs 0.000 title claims abstract description 16
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims abstract description 31
- 239000003814 drug Substances 0.000 claims abstract description 20
- 235000003255 Carthamus tinctorius Nutrition 0.000 claims abstract description 16
- 244000020518 Carthamus tinctorius Species 0.000 claims abstract description 16
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 16
- 239000000126 substance Substances 0.000 claims abstract description 10
- 238000010992 reflux Methods 0.000 claims abstract description 8
- 235000013402 health food Nutrition 0.000 claims abstract description 6
- 239000002552 dosage form Substances 0.000 claims abstract description 5
- 239000002775 capsule Substances 0.000 claims abstract description 3
- 239000008187 granular material Substances 0.000 claims abstract description 3
- 239000006187 pill Substances 0.000 claims abstract description 3
- 239000003826 tablet Substances 0.000 claims abstract description 3
- 239000003795 chemical substances by application Substances 0.000 claims abstract 3
- 239000012141 concentrate Substances 0.000 claims description 6
- 239000000463 material Substances 0.000 claims description 4
- 238000010828 elution Methods 0.000 claims description 2
- 239000000843 powder Substances 0.000 claims description 2
- 238000000926 separation method Methods 0.000 claims description 2
- 238000013268 sustained release Methods 0.000 claims description 2
- 239000012730 sustained-release form Substances 0.000 claims description 2
- 235000019441 ethanol Nutrition 0.000 claims 2
- PQMOXTJVIYEOQL-UHFFFAOYSA-N Cumarin Natural products CC(C)=CCC1=C(O)C(C(=O)C(C)CC)=C(O)C2=C1OC(=O)C=C2CCC PQMOXTJVIYEOQL-UHFFFAOYSA-N 0.000 claims 1
- FSOGIJPGPZWNGO-UHFFFAOYSA-N Meomammein Natural products CCC(C)C(=O)C1=C(O)C(CC=C(C)C)=C(O)C2=C1OC(=O)C=C2CCC FSOGIJPGPZWNGO-UHFFFAOYSA-N 0.000 claims 1
- 239000003349 gelling agent Substances 0.000 claims 1
- 229940100688 oral solution Drugs 0.000 claims 1
- 230000000694 effects Effects 0.000 abstract description 14
- 238000012360 testing method Methods 0.000 abstract description 13
- 238000000746 purification Methods 0.000 abstract description 7
- 230000009182 swimming Effects 0.000 abstract description 7
- 238000002360 preparation method Methods 0.000 abstract description 6
- 239000000725 suspension Substances 0.000 abstract description 6
- 238000000605 extraction Methods 0.000 abstract description 4
- 241000581650 Ivesia Species 0.000 abstract description 3
- 239000000499 gel Substances 0.000 abstract description 2
- 239000007788 liquid Substances 0.000 abstract description 2
- PFNFFQXMRSDOHW-UHFFFAOYSA-N spermine Chemical compound NCCCNCCCCNCCCN PFNFFQXMRSDOHW-UHFFFAOYSA-N 0.000 abstract 2
- 239000000872 buffer Substances 0.000 abstract 1
- 238000009776 industrial production Methods 0.000 abstract 1
- 229940063675 spermine Drugs 0.000 abstract 1
- 241000699670 Mus sp. Species 0.000 description 18
- 238000002474 experimental method Methods 0.000 description 12
- 241001465754 Metazoa Species 0.000 description 11
- 241000700159 Rattus Species 0.000 description 11
- 229940079593 drug Drugs 0.000 description 11
- 238000010171 animal model Methods 0.000 description 9
- 238000004458 analytical method Methods 0.000 description 8
- PNVNVHUZROJLTJ-UHFFFAOYSA-N venlafaxine Chemical compound C1=CC(OC)=CC=C1C(CN(C)C)C1(O)CCCCC1 PNVNVHUZROJLTJ-UHFFFAOYSA-N 0.000 description 7
- 241000699666 Mus <mouse, genus> Species 0.000 description 5
- 230000037396 body weight Effects 0.000 description 5
- 238000012346 open field test Methods 0.000 description 4
- 229960004688 venlafaxine Drugs 0.000 description 4
- 206010067484 Adverse reaction Diseases 0.000 description 3
- VVQNEPGJFQJSBK-UHFFFAOYSA-N Methyl methacrylate Chemical compound COC(=O)C(C)=C VVQNEPGJFQJSBK-UHFFFAOYSA-N 0.000 description 3
- 229920005372 Plexiglas® Polymers 0.000 description 3
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 3
- 229930006000 Sucrose Natural products 0.000 description 3
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 3
- 230000006838 adverse reaction Effects 0.000 description 3
- 239000001768 carboxy methyl cellulose Substances 0.000 description 3
- 239000003153 chemical reaction reagent Substances 0.000 description 3
- 239000012153 distilled water Substances 0.000 description 3
- 238000001647 drug administration Methods 0.000 description 3
- 238000003304 gavage Methods 0.000 description 3
- 230000000144 pharmacologic effect Effects 0.000 description 3
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 3
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 3
- 239000005720 sucrose Substances 0.000 description 3
- 229960002416 venlafaxine hydrochloride Drugs 0.000 description 3
- QYRYFNHXARDNFZ-UHFFFAOYSA-N venlafaxine hydrochloride Chemical compound [H+].[Cl-].C1=CC(OC)=CC=C1C(CN(C)C)C1(O)CCCCC1 QYRYFNHXARDNFZ-UHFFFAOYSA-N 0.000 description 3
- 230000003044 adaptive effect Effects 0.000 description 2
- 230000003542 behavioural effect Effects 0.000 description 2
- 230000003247 decreasing effect Effects 0.000 description 2
- 230000002996 emotional effect Effects 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 208000020016 psychiatric disease Diseases 0.000 description 2
- 238000001671 psychotherapy Methods 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 238000001228 spectrum Methods 0.000 description 2
- 230000000638 stimulation Effects 0.000 description 2
- -1 trimethylimipramine Chemical compound 0.000 description 2
- AHOUBRCZNHFOSL-YOEHRIQHSA-N (+)-Casbol Chemical compound C1=CC(F)=CC=C1[C@H]1[C@H](COC=2C=C3OCOC3=CC=2)CNCC1 AHOUBRCZNHFOSL-YOEHRIQHSA-N 0.000 description 1
- RTHCYVBBDHJXIQ-MRXNPFEDSA-N (R)-fluoxetine Chemical compound O([C@H](CCNC)C=1C=CC=CC=1)C1=CC=C(C(F)(F)F)C=C1 RTHCYVBBDHJXIQ-MRXNPFEDSA-N 0.000 description 1
- 208000031648 Body Weight Changes Diseases 0.000 description 1
- GDLIGKIOYRNHDA-UHFFFAOYSA-N Clomipramine Chemical compound C1CC2=CC=C(Cl)C=C2N(CCCN(C)C)C2=CC=CC=C21 GDLIGKIOYRNHDA-UHFFFAOYSA-N 0.000 description 1
- 206010011971 Decreased interest Diseases 0.000 description 1
- 206010012374 Depressed mood Diseases 0.000 description 1
- 229940123685 Monoamine oxidase inhibitor Drugs 0.000 description 1
- 206010027940 Mood altered Diseases 0.000 description 1
- AHOUBRCZNHFOSL-UHFFFAOYSA-N Paroxetine hydrochloride Natural products C1=CC(F)=CC=C1C1C(COC=2C=C3OCOC3=CC=2)CNCC1 AHOUBRCZNHFOSL-UHFFFAOYSA-N 0.000 description 1
- RMUCZJUITONUFY-UHFFFAOYSA-N Phenelzine Chemical compound NNCCC1=CC=CC=C1 RMUCZJUITONUFY-UHFFFAOYSA-N 0.000 description 1
- 208000010340 Sleep Deprivation Diseases 0.000 description 1
- 206010042458 Suicidal ideation Diseases 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 229930013930 alkaloid Natural products 0.000 description 1
- 229960000836 amitriptyline Drugs 0.000 description 1
- KRMDCWKBEZIMAB-UHFFFAOYSA-N amitriptyline Chemical compound C1CC2=CC=CC=C2C(=CCCN(C)C)C2=CC=CC=C21 KRMDCWKBEZIMAB-UHFFFAOYSA-N 0.000 description 1
- 230000036436 anti-hiv Effects 0.000 description 1
- 230000003064 anti-oxidating effect Effects 0.000 description 1
- 230000000259 anti-tumor effect Effects 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 230000004579 body weight change Effects 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 230000002060 circadian Effects 0.000 description 1
- 229960004606 clomipramine Drugs 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 229960005426 doxepin Drugs 0.000 description 1
- ODQWQRRAPPTVAG-GZTJUZNOSA-N doxepin Chemical compound C1OC2=CC=CC=C2C(=C/CCN(C)C)/C2=CC=CC=C21 ODQWQRRAPPTVAG-GZTJUZNOSA-N 0.000 description 1
- 238000002651 drug therapy Methods 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 238000002635 electroconvulsive therapy Methods 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 229930003935 flavonoid Natural products 0.000 description 1
- 150000002215 flavonoids Chemical class 0.000 description 1
- 235000017173 flavonoids Nutrition 0.000 description 1
- 229960002464 fluoxetine Drugs 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 239000005457 ice water Substances 0.000 description 1
- 229960004801 imipramine Drugs 0.000 description 1
- BCGWQEUPMDMJNV-UHFFFAOYSA-N imipramine Chemical compound C1CC2=CC=CC=C2N(CCCN(C)C)C2=CC=CC=C21 BCGWQEUPMDMJNV-UHFFFAOYSA-N 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 230000005923 long-lasting effect Effects 0.000 description 1
- 229960004644 moclobemide Drugs 0.000 description 1
- YHXISWVBGDMDLQ-UHFFFAOYSA-N moclobemide Chemical compound C1=CC(Cl)=CC=C1C(=O)NCCN1CCOCC1 YHXISWVBGDMDLQ-UHFFFAOYSA-N 0.000 description 1
- 239000002899 monoamine oxidase inhibitor Substances 0.000 description 1
- 229930014626 natural product Natural products 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 230000008520 organization Effects 0.000 description 1
- 229960002296 paroxetine Drugs 0.000 description 1
- 230000002085 persistent effect Effects 0.000 description 1
- 229960000964 phenelzine Drugs 0.000 description 1
- 238000001126 phototherapy Methods 0.000 description 1
- 229920001197 polyacetylene Polymers 0.000 description 1
- 229920000768 polyamine Polymers 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 238000004064 recycling Methods 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 229960002073 sertraline Drugs 0.000 description 1
- VGKDLMBJGBXTGI-SJCJKPOMSA-N sertraline Chemical compound C1([C@@H]2CC[C@@H](C3=CC=CC=C32)NC)=CC=C(Cl)C(Cl)=C1 VGKDLMBJGBXTGI-SJCJKPOMSA-N 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 150000003431 steroids Chemical class 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 229940126680 traditional chinese medicines Drugs 0.000 description 1
- 230000004584 weight gain Effects 0.000 description 1
- 235000019786 weight gain Nutrition 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/105—Plant extracts, their artificial duplicates or their derivatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/28—Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
- A61K36/286—Carthamus (distaff thistle)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
- A61K2236/333—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using mixed solvents, e.g. 70% EtOH
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/39—Complex extraction schemes, e.g. fractionation or repeated extraction steps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/50—Methods involving additional extraction steps
- A61K2236/55—Liquid-liquid separation; Phase separation
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Botany (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Mycology (AREA)
- Pharmacology & Pharmacy (AREA)
- Medical Informatics (AREA)
- Neurology (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- Alternative & Traditional Medicine (AREA)
- Pain & Pain Management (AREA)
- Psychiatry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Epidemiology (AREA)
- Neurosurgery (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Nutrition Science (AREA)
- Food Science & Technology (AREA)
- Polymers & Plastics (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
本发明属中药有效部位提取技术领域,提供一种抗抑郁的亚精胺有效部位的提取方法及亚精胺有效部位提取物的用途。干燥红花或红花药渣,60‑90%乙醇回流提取,减压浓缩,浓缩液经C18中压制备柱进行中压快速纯化,10‑100%乙醇或水洗脱、浓缩干燥即得亚精胺有效部位提取物。亚精胺有效部位能够明显减少小鼠强迫游泳试验和小鼠悬尾试验中的不动时间,亚精胺有效部位具有明显的抗抑郁作用。本发明提供的亚精胺有效部位是一种制备工艺简便、效果显著、安全可靠、易于工业化生产的天然抗抑郁有效物质群,可以制备成胶囊剂、片剂、颗粒剂、凝胶剂、缓释剂、口服液或滴丸剂等剂型用于抗抑郁药物或保健食品。
The invention belongs to the technical field of extraction of effective parts of traditional Chinese medicine, and provides a method for extracting antidepressant effective parts of spermidine and the application of the extract of effective parts of spermidine. Dried safflower or safflower dregs, reflux extraction with 60-90% ethanol, concentrated under reduced pressure, the concentrated solution was subjected to medium-pressure rapid purification on a C18 medium-pressure preparative column, eluted with 10-100% ethanol or water, concentrated and dried to obtain sub Spermine effective fraction extract. The effective part of spermidine can significantly reduce the immobility time in the mouse forced swimming test and the mouse tail suspension test, and the effective part of spermidine has obvious antidepressant effect. The active part of spermidine provided by the present invention is a natural antidepressant effective substance group with simple preparation process, significant effect, safety and reliability, and easy industrial production, and can be prepared into capsules, tablets, granules, gels, buffers, etc. Dosage forms such as release agent, oral liquid or drop pill are used for antidepressant drugs or health food.
Description
技术领域technical field
本发明属于中药有效部位提取技术领域,具体涉及一种抗抑郁的亚精胺有效部位的提取方法及亚精胺有效部位提取物的用途。The invention belongs to the technical field of extracting effective parts of traditional Chinese medicines, and in particular relates to a method for extracting effective parts of spermidine which is antidepressant and the use of extracts from effective parts of spermidine.
背景技术Background technique
抑郁症是一种常见的情感性精神疾病,主要表现为显著而持久地情绪低落,轻度抑郁症患者表现为心境不佳,兴趣缺失,严重者表现为悲观绝望,整日忧心忡忡,度日如年,痛不欲生,常有自杀倾向。抑郁症具有发病率高、复发率高和致残率高的特点。世界卫生组织已经将其列为十大重型疾病之一,随着社会经济的发展,生活节奏的加快,人们的压力增加,各种情感冲击加大,造成抑郁症发病率逐年增高。抑郁症严重的危害性迫切要求研究者加速研究以及开发疗效更好的安全性更高的抗抑郁药物。Depression is a common emotional mental illness, mainly manifested as significant and persistent low mood. Patients with mild depression manifest as a bad mood and loss of interest. In severe cases, they manifest as pessimism and despair. , often suicidal tendencies. Depression has the characteristics of high incidence rate, high relapse rate and high disability rate. The World Health Organization has listed it as one of the top ten serious diseases. With the development of society and economy, the pace of life has accelerated, people's pressure has increased, and various emotional impacts have increased, resulting in an increase in the incidence of depression year by year. The serious harm of depression urgently requires researchers to accelerate research and develop antidepressant drugs with better efficacy and higher safety.
抑郁症的治疗方法较多,如心理治疗、睡眠剥夺治疗、光疗和电痉挛治疗等,但仍以药物治疗为主,同时辅以心理治疗。目前治疗抑郁症的药物主要以化学药物为主,如三环类(临床常用丙咪嗪、阿米替林、多虑平、三甲基丙咪嗪、氯丙咪嗪等)、单胺氧化酶抑制剂(临床常用苯乙肼、异唑肼、环丙胺、吗氯贝胺等)、选择性5-HT重摄取抑制剂(临床常用氟西汀、帕罗西汀、舍曲林、西普肽兰等)等,但这些化学药物存在治疗谱窄、耐受性差、毒副作用大、价格昂贵等问题。因此,从作用持久、不良反应发生率低的天然产物中发现和创制具有良好抗抑郁功效的药物,已成为当前国内外研究的热点。There are many treatment methods for depression, such as psychotherapy, sleep deprivation therapy, phototherapy and electroconvulsive therapy, but drug therapy is still the main method, supplemented by psychotherapy. At present, the drugs used to treat depression are mainly chemical drugs, such as tricyclics (imipramine, amitriptyline, doxepin, trimethylimipramine, clomipramine, etc.), monoamine oxidase inhibitors, etc. (Phenelzine, isofazilazine, cypromine, moclobemide, etc. are commonly used in clinical practice), selective 5-HT reuptake inhibitors (fluoxetine, paroxetine, sertraline, siptylan, etc. are commonly used in clinical practice) However, these chemical drugs have problems such as narrow therapeutic spectrum, poor tolerance, large toxic and side effects, and high price. Therefore, discovering and creating drugs with good antidepressant effects from natural products with long-lasting effects and low incidence of adverse reactions has become a hot research topic at home and abroad.
目前,从红花中已分离得到250多个化学成分,包括黄酮类、生物碱类、聚炔类、烷基二醇类、有机酸类、甾体类、亚精胺类等。其中,亚精胺衍生物即具有(H2N(CH2)3NH(CH2)4NH2)结构单元的多胺类化合物,是红花中的一类特殊成分,文献报道其显示出了广泛的生物活性,如抗HIV病毒、抗肿瘤、抗氧化等,但是红花中的亚精胺在神经和精神系统疾病特别是抑郁症方面的作用未见文献报道,且红花中一类亚精胺的制备也未见报道。At present, more than 250 chemical components have been isolated from safflower, including flavonoids, alkaloids, polyacetylenes, alkyl glycols, organic acids, steroids, spermidine, etc. Among them, spermidine derivatives are polyamine compounds with (H 2 N(CH 2 ) 3 NH(CH 2 ) 4 NH 2 ) structural units, which are a kind of special components in safflower. It is reported in the literature that they show It has a wide range of biological activities, such as anti-HIV virus, anti-tumor, anti-oxidation, etc., but the role of spermidine in safflower in nervous and mental diseases, especially depression, has not been reported in the literature, and a class of safflower The preparation of spermidine has not been reported yet.
发明内容Contents of the invention
本发明的目的在于提供一种抗抑郁的亚精胺有效部位的提取方法及亚精胺有效部位提取物的用途。The purpose of the present invention is to provide a method for extracting the antidepressant effective part of spermidine and the application of the extract of the effective part of spermidine.
为实现上述目的,本发明提供如下技术方案:一种抗抑郁的亚精胺有效部位的提取方法,具体步骤如下:取干燥红花或红花药渣,60-90%乙醇回流提取1-2次,减压浓缩,浓缩液经C18中压制备柱进行中压快速纯化,W1/W2为1-10,所述W1为待分离样品质量以mg计,W2为C18柱分离材料的质量以g计;10-100%乙醇或水洗脱、浓缩干燥即得亚精胺有效部位提取物。In order to achieve the above object, the present invention provides the following technical scheme: a method for extracting the effective part of antidepressant spermidine, the specific steps are as follows: take dried safflower or safflower dregs, and reflux 60-90% ethanol to extract 1-2 time, concentrated under reduced pressure, the concentrated solution is subjected to medium-pressure rapid purification through a C18 medium-pressure preparative column, W1/W2 is 1-10, the W1 is the quality of the sample to be separated in mg, and W2 is the quality of the C18 column separation material in g Calculated; 10-100% ethanol or water elution, concentration and drying to obtain the effective fraction extract of spermidine.
所获得的亚精胺有效部位提取物含有4个不同构型的三香豆素酰基取代的亚精胺类物质,总含量为50%以上。The obtained spermidine active part extract contains four different configurations of tricoumarinyl-substituted spermidine substances, and the total content is more than 50%.
亚精胺有效部位提取物的应用,所述亚精胺有效部位提取物在制备抗抑郁的药物或保健食品中的应用。The application of the extract of effective part of spermidine, the application of the extract of effective part of spermidine in the preparation of antidepressant medicine or health food.
所述抗抑郁的药物为亚精胺有效部位提取物加入药学可接受的辅料制成药剂学可接受的常规剂型。The antidepressant medicine is prepared by adding the extract of effective parts of spermidine and pharmaceutically acceptable auxiliary materials into a pharmaceutically acceptable conventional dosage form.
所述剂型为胶囊剂、片剂、散剂、颗粒剂、凝胶剂、缓释剂、口服液或滴丸剂。The dosage form is capsule, tablet, powder, granule, gel, sustained release, oral liquid or drop pill.
所述的亚精胺有效部位提取物含有四个不同构型的三香豆酰基取代的亚精胺类物质(结构见图1),总含量达50%以上,详见附图2。The extract of the active part of spermidine contains four different configurations of tricoumaryl-substituted spermidine substances (see Figure 1 for the structure), with a total content of more than 50%, see Figure 2 for details.
本发明具有如下明显的优点:The present invention has the following obvious advantages:
本发明进一步优化了用作亚精胺有效部位制备工艺的流程,同时对于进一步循环利用中药渣也具有重要的意义。The present invention further optimizes the process used as a preparation process for the effective part of spermidine, and meanwhile has important significance for the further recycling of traditional Chinese medicine dregs.
本发明发现了亚精胺有效部位的药用功能,将其用于抗抑郁作用,并可制备成预防和/或治疗抑郁症的药物,从而为亚精胺有效部位药用或保健功能的临床应用开拓新的领域。The present invention discovers the medicinal function of the effective part of spermidine, uses it for antidepressant effect, and can be prepared as a medicine for preventing and/or treating depression, so as to be the clinical application of the medicinal or health care function of the effective part of spermidine. Applications break new ground.
经典抗抑郁动物模型实验结果表明亚精胺有效部位具有明显的抗抑郁作用。The results of classic antidepressant animal model experiments show that the effective fraction of spermidine has obvious antidepressant effect.
本发明的亚精胺有效部位药理作用较强,用于预防、调理和治疗抑郁症的功效功效明显、起效较快、不良反应较小、价格低廉,具有良好的应用前景。The effective part of the spermidine of the present invention has strong pharmacological action, obvious efficacy for preventing, regulating and treating depression, quick onset, small adverse reaction, low price, and good application prospect.
本发明可单独使用亚精胺有效部位制备预防和治疗抑郁症的药物或保健食品。The present invention can use the active part of spermidine alone to prepare medicine or health food for preventing and treating depression.
附图说明Description of drawings
图1为4个亚精胺的化学结构式;Fig. 1 is the chemical structural formula of 4 spermidines;
图2为红花药渣中亚精胺类化合物HPLC图谱 (λ=300 nm)。Figure 2 is the HPLC spectrum of spermidine compounds in safflower dregs (λ=300 nm).
具体实施方式Detailed ways
结合具体实施例,进一步阐述本发明。但这些实施例仅限于说明本发明而不用于限制本发明的范围。The present invention is further described in conjunction with specific embodiments. However, these examples are only for illustrating the present invention and are not intended to limit the scope of the present invention.
实施例中未注明具体实验条件的实验方法,通常按照常规条件操作,或按照生产厂家推荐的条件操作。For the experimental methods that do not specify specific experimental conditions in the examples, they are usually operated under conventional conditions, or according to the conditions recommended by the manufacturer.
实施例1:一种具有抗抑郁作用的亚精胺有效部位的制备方法,包括以下步骤:取干燥红花药渣,60%乙醇回流提取1次,减压浓缩,浓缩液经C18中压制备柱进行中压快速纯化制备,W1/W2为1(mg/g),60%乙醇洗脱、浓缩干燥即得亚精胺有效部位,其得率可达95.79%。Example 1: A method for preparing the effective part of spermidine with antidepressant effect, comprising the following steps: take dried safflower dregs, reflux extraction with 60% ethanol once, concentrate under reduced pressure, and prepare the concentrated solution through C18 medium pressure The column is prepared by medium-pressure rapid purification, W1/W2 is 1 (mg/g), eluted with 60% ethanol, concentrated and dried to obtain the effective part of spermidine, and the yield can reach 95.79%.
经过分析:亚精胺有效部位提取物含有四个不同构型的三香豆酰基取代的亚精胺类物质,具体结构见图1,总含量达50%以上,详见附图2。After analysis: the extract of the active part of spermidine contains four different configurations of tricoumaryl-substituted spermidine substances. The specific structure is shown in Figure 1, and the total content is more than 50%. See Figure 2 for details.
实施例2:一种具有抗抑郁作用的亚精胺有效部位的制备方法,包括以下步骤:取干燥红花药渣,75%乙醇回流提取1次,减压浓缩,浓缩液经C18中压制备柱进行中压快速纯化制备,W1/W2为5(mg/g),50%乙醇洗脱、浓缩干燥即得亚精胺有效部位,其得率可达97.22%。Example 2: A method for preparing the effective part of spermidine with antidepressant effect, comprising the following steps: take dried safflower dregs, reflux extraction with 75% ethanol once, concentrate under reduced pressure, and prepare the concentrated solution through C18 medium pressure The column was prepared by medium-pressure rapid purification, W1/W2 was 5 (mg/g), eluted with 50% ethanol, concentrated and dried to obtain the effective fraction of spermidine, and the yield could reach 97.22%.
实施例3:一种具有抗抑郁作用的亚精胺有效部位的制备方法,包括以下步骤:取干燥红花药渣,90%乙醇回流提取1次,减压浓缩,浓缩液经C18中压制备柱进行中压快速纯化制备,W1/W2为10(mg/g),40%乙醇洗脱、浓缩干燥即得亚精胺有效部位,其得率可达92.79%。Example 3: A method for preparing the effective part of spermidine with antidepressant effect, comprising the following steps: take dried safflower dregs, extract once with 90% ethanol under reflux, concentrate under reduced pressure, and prepare the concentrated solution through C18 medium pressure The column was prepared by medium-pressure rapid purification, W1/W2 was 10 (mg/g), eluted with 40% ethanol, concentrated and dried to obtain the effective fraction of spermidine, and the yield could reach 92.79%.
实施例4 :一种具有抗抑郁作用的亚精胺有效部位的制备方法,包括以下步骤:取干燥红花药渣,75%乙醇回流提取2次,减压浓缩,浓缩液经C18中压制备柱进行中压快速纯化制备,W1/W2为5(mg/g),用50%乙醇作洗脱溶剂、浓缩干燥即得亚精胺有效部位,其得率可达93.52%。Embodiment 4: a kind of preparation method of the active part of spermidine with antidepressant effect, comprises the following steps: get dry safflower dregs, 75% ethanol reflux extracts 2 times, concentrate under reduced pressure, concentrated solution is prepared through C18 medium pressure The column was prepared by medium-pressure rapid purification, W1/W2 was 5 (mg/g), 50% ethanol was used as the eluting solvent, concentrated and dried to obtain the effective fraction of spermidine, and the yield could reach 93.52%.
实施例5:一种具有抗抑郁作用的亚精胺有效部位的制备方法,包括以下步骤:取干燥红花,75%乙醇回流提取1次,减压浓缩,浓缩液经C18中压制备柱进行中压快速纯化制备,W1/W2为5(mg/g),50%乙醇洗脱、浓缩干燥即得亚精胺有效部位,其得率可达90.32%。Example 5: A method for preparing the effective part of spermidine with antidepressant effect, comprising the following steps: take dried safflower, extract once with 75% ethanol under reflux, concentrate under reduced pressure, and carry out the concentrated solution through a C18 medium pressure preparation column It is prepared by medium-pressure rapid purification, W1/W2 is 5 (mg/g), eluted with 50% ethanol, concentrated and dried to obtain the effective part of spermidine, and the yield can reach 90.32%.
实施例6:小鼠强迫游泳试验Embodiment 6: Mouse forced swimming test
实验仪器与试剂:动物行为视频分析系统(成都泰盟科技有限公司),温度计,计时器,有机玻璃缸,动物灌胃针。总亚精胺有效部位提取物,羧甲基纤维素钠(CMC-Na,天津市凯通化学试剂有限公司),盐酸文拉法辛(成都康弘药业集团股份有限公司)。Experimental instruments and reagents: animal behavior video analysis system (Chengdu Taimeng Technology Co., Ltd.), thermometer, timer, plexiglass cylinder, animal gavage needle. Total spermidine active fraction extract, sodium carboxymethylcellulose (CMC-Na, Tianjin Kaitong Chemical Reagent Co., Ltd.), venlafaxine hydrochloride (Chengdu Kanghong Pharmaceutical Group Co., Ltd.).
实验动物及给药:雄性ICR小鼠(北京维通利华实验动物技术有限公司,许可证号:SCXK(京)2016-0006),18-22g,适应性喂养1周以后,随机分为5组,每组12只。文拉法辛给药剂量为0.05g/kg,总亚精胺有效部位提取物剂量为0.1g/kg、0.05g/kg、0.025g/kg,空白对照组给予等体积蒸馏水。各组动物依据体重每天灌胃1次,每次1ml/20g,连续14天。Experimental animals and drug administration: Male ICR mice (Beijing Weitong Lihua Experimental Animal Technology Co., Ltd., license number: SCXK (Beijing) 2016-0006), 18-22g, after adaptive feeding for 1 week, were randomly divided into 5 Group, 12 in each group. The dosage of venlafaxine was 0.05g/kg, the dosage of total spermidine effective part extract was 0.1g/kg, 0.05g/kg, 0.025g/kg, and the blank control group was given an equal volume of distilled water. Animals in each group were given intragastric administration once a day according to body weight, 1ml/20g each time, for 14 consecutive days.
实验方法:末次给药1h后,将小鼠置于高25cm,直径10cm,水深15cm的有机玻璃缸中,水温为23± 2 ℃。用动物行为视频分析系统记录6min内小鼠的游泳行为状况,分析后4min内小鼠强迫游泳的不动时间(指小鼠在水中停止挣扎或显示漂浮状态,仅有微小的肢体运动以保持头部浮在水面)。Experimental method: 1 hour after the last administration, the mice were placed in a plexiglass tank with a height of 25cm, a diameter of 10cm, and a water depth of 15cm. The water temperature was 23±2°C. Use the animal behavior video analysis system to record the swimming behavior of the mice within 6 minutes, and the immobility time of the mice forced to swim within 4 minutes after analysis (meaning that the mice stop struggling or show a floating state in the water, and only have small limb movements to keep their heads. floating on the water).
实验结果:实验前及实验结束后分别称定各组小鼠体重,观察亚精胺对小鼠体重的影响,结果间表1,实验数据由Mean±SD 表示。由表1可知,实验前及实验后各组小鼠体重变化没有显著性差异,说明药物本身并不影响动物体重,没有明显不良反应。Experimental results: Before the experiment and after the experiment, the mice in each group were weighed, and the effect of spermidine on the mouse weight was observed. The results are shown in Table 1, and the experimental data are represented by Mean±SD. It can be seen from Table 1 that there was no significant difference in the weight change of the mice in each group before and after the experiment, indicating that the drug itself did not affect the weight of the animals, and there was no obvious adverse reaction.
表1 亚精胺对实验前后小鼠体重的影响(g)Table 1 Effect of spermidine on body weight of mice before and after experiment (g)
亚精胺对小鼠强迫游泳试验中不动时间的影响见表2,数据由Mean ± SD表示。由表2可知,灌胃给药14天后,各给药组不动时间均有所减少,且与空白对照组比较,除亚精胺高剂量组外都具有显著性差异(P<0.05或P<0.01)。The effect of spermidine on the immobility time in the forced swimming test of mice is shown in Table 2, and the data are represented by Mean ± SD. It can be seen from Table 2 that after 14 days of intragastric administration, the immobility time of each administration group was reduced, and compared with the blank control group, except for the high-dose spermidine group, there was a significant difference ( P<0.05 or P <0.01 ).
表2 亚精胺对小鼠强迫游泳实验中不动时间的影响(n=12)Table 2 Effect of spermidine on immobility time in forced swimming test of mice (n=12)
与空白对照组比较:*P<0.05有显著性差异,**P<0.01有极显著性差异。实施例7小鼠悬尾试验Compared with blank control group: * P<0.05 has significant difference, ** P<0.01 has extremely significant difference. Embodiment 7 mouse tail suspension test
实验仪器与试剂:动物行为视频分析系统(成都泰盟科技有限公司),温度计,计时器,有机玻璃缸,动物灌胃针。总亚精胺有效部位提取物,羧甲基纤维素钠(CMC-Na,天津市凯通化学试剂有限公司),盐酸文拉法辛(成都康弘药业集团股份有限公司)。Experimental instruments and reagents: animal behavior video analysis system (Chengdu Taimeng Technology Co., Ltd.), thermometer, timer, plexiglass cylinder, animal gavage needle. Total spermidine active fraction extract, sodium carboxymethylcellulose (CMC-Na, Tianjin Kaitong Chemical Reagent Co., Ltd.), venlafaxine hydrochloride (Chengdu Kanghong Pharmaceutical Group Co., Ltd.).
实验动物及给药:实验动物及给药同实施例6。Experimental animals and administration: Experimental animals and administration are the same as in Example 6.
实验方法:末次给药1h后,将小鼠尾尖1cm处黏贴于悬挂钩上,并且手托小鼠将其挂入动物行为视频分析系统观察箱中 ,记录6min内小鼠的绝望行为,分析后4min内小鼠的不动时间。Experimental method: 1 hour after the last administration, stick the tail tip of the mouse on the hanging hook at 1 cm, and hang the mouse into the observation box of the animal behavior video analysis system, and record the desperate behavior of the mouse within 6 minutes. The immobility time of mice within 4 min after analysis.
实验结果:亚精胺对小鼠悬尾试验中不动时间的影响如表3所示,实验数据由Mean± SD 表示。由表3可知,与小鼠强迫游泳试验结果一致,亚精胺有效部位中剂量组(0.05g/kg)亚精胺有效部位低剂量组(0.025g/kg)均能减少小鼠悬尾实验中的不动时间,与空白对照组比较都具有显著性差异(P<0.05或P<0.01),且呈现一定的剂量依赖性。小鼠强迫游泳试验和小鼠悬尾试验结果都表明亚精胺有效部位具有明显的抗抑郁作用,其功效与经典抗抑郁化学药物文拉法辛相当。Experimental results: The effect of spermidine on the immobility time in the tail suspension test of mice is shown in Table 3, and the experimental data are represented by Mean±SD. It can be seen from Table 3 that, consistent with the results of the forced swimming test in mice, the middle dose group (0.05g/kg) of the active part of spermidine and the low dose group (0.025g/kg) of the effective part of spermidine can reduce the tail suspension test of mice. Compared with the blank control group, there was a significant difference ( P<0.05 or P<0.01 ) in the immobility time in the control group, and it showed a certain dose dependence. The results of the forced swimming test in mice and the tail suspension test in mice showed that the active part of spermidine has obvious antidepressant effect, and its efficacy is equivalent to that of the classic antidepressant chemical drug venlafaxine.
表3 亚精胺对小鼠悬尾实验中不动时间的影响(n=12)Table 3 Effect of spermidine on immobility time in mouse tail suspension test (n=12)
与空白对照组比较:*P<0.05有显著性差异,**P<0.01有极显著性差异Compared with the blank control group: * P<0.05 has a significant difference, ** P<0.01 has a very significant difference
综上所述,本实验结果表明亚精胺有效部位能够明显减少行为绝望抑郁症动物模型小鼠中的不动时间。因此,可以确定亚精胺有效部位具有显著的抗抑郁作用,可用于制备预防和/或治疗抑郁症的药物或保健食品。In summary, the results of this experiment show that the effective part of spermidine can significantly reduce the immobility time in the animal model mice of behavioral hopelessness and depression. Therefore, it can be determined that the effective part of spermidine has significant antidepressant effect, and can be used to prepare medicine or health food for preventing and/or treating depression.
实施例8:慢性不可预知应激模型(CUMS)Example 8: Chronic Unpredictable Stress Model (CUMS)
实验仪器与试剂:动物行为视频分析系统(成都泰盟科技有限公司),开场试验箱(自制),温度计,计时器,动物灌胃针,1000 ml量筒,秒表,夹子,医用胶带。亚精胺有效部位,蔗糖(天津市光复科技发展有限公司),羧甲基纤维素钠(CMC-Na,天津市凯通化学试剂有限公司),盐酸文拉法辛(成都康弘药业集团股份有限公司)。Experimental instruments and reagents: animal behavior video analysis system (Chengdu Taimeng Technology Co., Ltd.), opening test box (self-made), thermometer, timer, animal gavage needle, 1000 ml measuring cylinder, stopwatch, clips, medical tape. Effective part of spermidine, sucrose (Tianjin Guangfu Technology Development Co., Ltd.), sodium carboxymethylcellulose (CMC-Na, Tianjin Kaitong Chemical Reagent Co., Ltd.), venlafaxine hydrochloride (Chengdu Kanghong Pharmaceutical Group Co., Ltd. Ltd).
实验动物及给药:雄性SD大鼠(北京维通利华实验动物技术有限公司,许可证号:SCXK(京)2016-0006),180-220g,适应性喂养1周以后,随机分为6组,每组10只。文拉法辛给药剂量为0.05g/kg,总亚精胺有效部位提取物高、中、低剂量为34.6mg/kg、17.3mg/kg、8.65mg/kg,空白对照和模型对照组给予等体积蒸馏水。各组动物依据体重每天灌胃1次,每次10ml/200g,连续28天。Experimental animals and drug administration: male SD rats (Beijing Weitong Lihua Experimental Animal Technology Co., Ltd., license number: SCXK (Beijing) 2016-0006), 180-220g, after 1 week of adaptive feeding, were randomly divided into 6 Group, 10 in each group. The dose of venlafaxine was 0.05g/kg, the high, medium and low doses of total spermidine effective fraction extracts were 34.6mg/kg, 17.3mg/kg, 8.65mg/kg, and the blank control group and model control group were given equal volume of distilled water. Animals in each group were given intragastric administration once a day, 10ml/200g each time, for 28 consecutive days according to body weight.
CUMS抑郁模型建立:刺激因子包括:禁食、禁水、束缚、夹尾、超声刺激、4℃冰水浴、足底电击、热刺激、昼夜紊乱。每天随机给予1种刺激,每种刺激不超过4次。除空白对照组外,其余各组均单笼饲养并实施造模程序,造模时间为28d。造模开始后同时灌胃给药,药物组给予相应浓度药物,模型组及空白对照组给予等体积蒸馏水。Establishment of CUMS depression model: stimulating factors include: fasting, water deprivation, restraint, tail pinching, ultrasonic stimulation, 4°C ice water bath, plantar electric shock, thermal stimulation, and circadian disturbance. One stimulus was randomly given every day, and each stimulus was no more than 4 times. Except for the blank control group, the rest of the groups were reared in single cages and implemented the modeling procedure, and the modeling time was 28 days. After the start of modeling, drugs were given by intragastric administration at the same time. The drug group was given corresponding concentrations of drugs, and the model group and blank control group were given equal volumes of distilled water.
检测指标:Detection Indicator:
体重:在实验第0、7、14、21、28d称量大鼠体重。Body weight: the rats were weighed on the 0th, 7th, 14th, 21st and 28th day of the experiment.
糖水偏爱率:造模开始及结束测定大鼠1%糖水消耗量,计算糖水偏爱率。Sugar water preference rate: measure the 1% sugar water consumption of rats at the beginning and end of modeling, and calculate the sugar water preference rate.
旷场实验:大鼠放入旷场箱5min,记录后4min内大鼠的穿越格数和直立次数。Open field test: Rats were placed in the open field box for 5 minutes, and the number of crossing grids and upright times of the rats within 4 minutes after recording.
实验结果:亚精胺有效部位对CUMS大鼠体重、糖水偏爱率、旷场实验等指标的影响由表4、5、6可知:亚精胺有效部位可以改善由CUMS造模应激引起的大鼠体重增长缓慢、在旷场实验中活动力降低和对蔗糖甜度的偏好下降,一定程度上表明亚精胺有效部位具有良好的抗抑郁作用,其药理活性达到或超过抗抑郁西药文拉法辛。Experimental results: the effect of the effective part of spermidine on the body weight, sugar water preference rate, open field test and other indicators of CUMS rats. It can be seen from Table 4, 5, and 6 that the effective part of spermidine can improve the stress caused by CUMS modeling. The slow weight growth of rats, decreased activity in the open field test, and decreased preference for sucrose sweetness indicate to a certain extent that the effective fraction of spermidine has a good antidepressant effect, and its pharmacological activity reaches or exceeds that of the antidepressant Western drug Venlafa pungent.
表4 造模及给药对大鼠体重变化的影响(x ± s, n=10, 单位:g)Table 4 Effects of modeling and administration on body weight changes in rats (x ± s, n=10, unit: g)
与模型对照组相比:**p<0.01, *p<0.05 与空白对照组相比:## p<0.01, # p<0.05 Compared with the model control group: ** p<0.01 , * p<0.05 Compared with the blank control group: ## p<0.01 , # p<0.05
表5 造模及给药对CUMS大鼠糖水偏爱率的影响(x ± s, n=10)Table 5 Effects of modeling and drug administration on sugar water preference rate of CUMS rats (x ± s, n=10)
与模型对照组相比:**p<0.01, *p<0.05 与空白对照组相比:## p<0.01, # p<0.05 Compared with the model control group: ** p<0.01 , * p<0.05 Compared with the blank control group: ## p<0.01 , # p<0.05
表6 亚精胺有效部位对CUMS大鼠旷场实验的影响Table 6 Effects of the effective part of spermidine on the open field test of CUMS rats
与模型对照组相比:**p<0.01, *p<0.05 与空白对照组相比:## p<0.01, # p<0.05 Compared with the model control group: ** p<0.01 , * p<0.05 Compared with the blank control group: ## p<0.01 , # p<0.05
综上所述,本实验结果表明亚精胺有效部位能够明显减少行为绝望抑郁症动物模型小鼠中的不动时间,改善由CUMS造模应激引起的大鼠体重增长缓慢、在旷场实验中活动力降低和对蔗糖甜度的偏好下降,一定程度上表明其具有良好的抗抑郁作用,其药理活性达到或超过抗抑郁西药文拉法辛。因此,可以确定亚精胺有效部位具有显著的抗抑郁作用,可用于制备预防和/或治疗抑郁症的药物或保健食品。In summary, the results of this experiment show that the effective part of spermidine can significantly reduce the immobility time in the animal model mice of behavioral hopelessness and depression, and improve the slow weight gain of rats caused by the stress of CUMS modeling, and the improvement in open field experiments. The decrease in activity and the preference for sucrose sweetness indicate that it has a good antidepressant effect to a certain extent, and its pharmacological activity reaches or exceeds that of the antidepressant western drug venlafaxine. Therefore, it can be determined that the effective part of spermidine has significant antidepressant effect, and can be used to prepare medicine or health food for preventing and/or treating depression.
Claims (5)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201910596030.6A CN110279738A (en) | 2019-07-03 | 2019-07-03 | A kind of extracting method of antidepressant spermidine active component and the purposes of spermidine effective part extract |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201910596030.6A CN110279738A (en) | 2019-07-03 | 2019-07-03 | A kind of extracting method of antidepressant spermidine active component and the purposes of spermidine effective part extract |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN110279738A true CN110279738A (en) | 2019-09-27 |
Family
ID=68020850
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201910596030.6A Pending CN110279738A (en) | 2019-07-03 | 2019-07-03 | A kind of extracting method of antidepressant spermidine active component and the purposes of spermidine effective part extract |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN110279738A (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN113045449A (en) * | 2021-02-04 | 2021-06-29 | 深圳大学 | Coumaroylspermine derivative and extraction method and application thereof |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103508912A (en) * | 2013-09-04 | 2014-01-15 | 中国科学院西北高原生物研究所 | Method for separation and preparation of spermidines from safflower by employing high-speed counter-current chromatography |
| CN105158355A (en) * | 2015-08-12 | 2015-12-16 | 山西大学 | Method for rapidly measuring content of four spermidine ingredients in carthamus tinctorius simultaneously |
-
2019
- 2019-07-03 CN CN201910596030.6A patent/CN110279738A/en active Pending
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103508912A (en) * | 2013-09-04 | 2014-01-15 | 中国科学院西北高原生物研究所 | Method for separation and preparation of spermidines from safflower by employing high-speed counter-current chromatography |
| CN105158355A (en) * | 2015-08-12 | 2015-12-16 | 山西大学 | Method for rapidly measuring content of four spermidine ingredients in carthamus tinctorius simultaneously |
Non-Patent Citations (2)
| Title |
|---|
| 袁茂叶等: "红花中亚精胺衍生物分离纯化及其抑制[3H]-5-HT再摄取的作用", 《山西医科大学学报》 * |
| 靳玉芳等: "正交试验优选红花注射液药渣中亚精胺的提取工艺及其含量测定", 《化学研究与应用》 * |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN113045449A (en) * | 2021-02-04 | 2021-06-29 | 深圳大学 | Coumaroylspermine derivative and extraction method and application thereof |
| CN113045449B (en) * | 2021-02-04 | 2022-04-19 | 深圳大学 | Coumaroyl spermidine derivative and its extraction method and application |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NO338015B1 (en) | Pharmaceutical composition for use in the treatment of depression and method of preparation thereof | |
| JP4993523B2 (en) | Use of 20 (S) -protopanaxadiol for the production of antidepressants | |
| CN102274227B (en) | Application of tetrandrine in preparation of drug for prevention and/or treatment of depression | |
| CN106511260B (en) | A kind of Berberine hydrochloride takes orally pellet xerogel and its preparation method and application | |
| WO2011047576A1 (en) | Use of albiflorin for anti-depression | |
| CN101791314B (en) | Application of crocin in preparing hypnotic drug | |
| CN102014931B (en) | Use and preparation of paeoniflorin and the composition thereof | |
| CN101347524A (en) | Traditional Chinese medicine composition for treating depression and preparation method thereof | |
| CN103980197B (en) | Spina Date Seed alkaloid monomer composition acid Lee alkali and preparation method thereof and application | |
| CN104490972A (en) | Pharmaceutical composition for treating and preventing depression and preparation method of pharmaceutical composition | |
| WO2009070921A1 (en) | Antimelancholic medicine prepared with jujube camp materials | |
| CN101288761B (en) | Chinese tmedicine preparation for treating depression and its preparation method | |
| CN110279738A (en) | A kind of extracting method of antidepressant spermidine active component and the purposes of spermidine effective part extract | |
| CN106397437A (en) | Club moss alkaloid compound and medicine composition therefore, as well as preparation method and application thereof | |
| CN102178721B (en) | Application of fiveleaf gynostemma herb suspension and extract to preparation of drug for treating and resisting depression | |
| CN105919991B (en) | Application of the euparin in preparation medicament for treatment of depression | |
| CN103655559B (en) | Horned artemisia ester alkali compounds is preparing the application in anti-breast cancer medicines | |
| CN104491075A (en) | Refined part of total gardenia crocin with anti-depression effect as well as preparation method and application of refined part | |
| CN100348228C (en) | New use of powder for regulating liver and spleen and its active part | |
| CN112494595B (en) | Traditional Chinese medicine composition and preparation method and application thereof | |
| CN111358826B (en) | Total flavone extract with antidepressant effect, and preparation method and application thereof | |
| CN108542898A (en) | Purposes of the cajanin and combinations thereof in preparing medicament for treatment of depression | |
| CN101732301A (en) | Application of chlorogenic acid in preparing medicines for preventing and curing senile dementia | |
| CN101502536B (en) | Cedar total flavone and preparation method and medical application thereof | |
| CN114224922A (en) | A kind of preparation method and application of antidepressant ginkgo biloba extract |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20190927 |